Financials
Value 202020212022202320242025 TTM Selling/general/admin expenses 188.27 M567 M1.13 B1.75 B1.32 B1.15 B 965 M Research & development 1.37 B1.99 B3.29 B4.84 B4.54 B3.13 B 2.88 B Operating income -763.14 M13.3 B9.42 B-4.24 B-3.94 B-3.07 B -3.32 B Non-Operating Income, Total -53.84 M-65 M124 M323 M381 M365 M 282 M Interest expense, net of interest capitalized 9.89 M17 M29 M38 M24 M3 M — Non-Operating Income, excl. Interest Expenses -57.65 M-53 M140 M409 M444 M370 M 331 M Unusual income/expense -6.08 M-29 M-45 M-124 M-87 M-8 M -49 M Pretax income -744.51 M13.29 B9.57 B-3.94 B-3.61 B-2.77 B -3.09 B Equity in earnings ———-35 M-52 M-8 M -2 M Taxes 2.55 M1.08 B1.21 B772 M-46 M54 M 64 M Non-controlling/minority interest —————— — After tax other income/expense ——-28 M-7 M-60 M-77 M -51 M Net income before discontinued operations -747.06 M12.2 B8.36 B-4.71 B-3.56 B-2.82 B -3.15 B Discontinued operations —————— — Net income -747.06 M12.2 B8.36 B-4.71 B-3.56 B-2.82 B -3.15 B Dilution adjustment 0————— — Preferred dividends 0————— — Diluted net income available to common stockholders -747.06 M12.2 B8.36 B-4.71 B-3.56 B-2.82 B -3.15 B Basic earnings per share (Basic EPS) —30.3121.26-12.33-9.28-7.26 -7.98 Diluted earnings per share (Diluted EPS) —28.2920.12-12.33-9.28-7.26 -7.98 Average basic shares outstanding —403 M394 M382 M384 M389 M — Diluted shares outstanding —431 M416 M382 M384 M389 M — EBITDA -731.89 M13.53 B9.77 B-3.62 B-3.76 B-2.86 B -3.09 B EBIT -763.14 M13.3 B9.42 B-4.24 B-3.94 B-3.07 B -3.32 B Cost of revenue 7.93 M2.62 B5.42 B4.69 B1.46 B868 M 1.71 B Other cost of goods sold ——1.92 B2.34 B555 M315 M 297 M Depreciation & amortization (cash flow) 31.25 M232 M348 M617 M185 M211 M 229 M
News
Moderna Borrows $2 Billion To Expand Oncology Business - Moderna (NASDAQ:MRNA)
S&P 500 Top Stock Gainers Today, 8/26/26 - TipRanks.com
Merck Stock Hits New 52-Week High: What's Driving the Rally?
Vertex Pharmaceuticals Up 15% in a Month: How to Play the Stock
Moderna Stock Dips Wednesday: What's Going On? - Moderna (NASDAQ:MRNA)
EXCLUSIVE: Sunshine Biopharma Advances Vaccine Strategy for Lung Cancer - Sunshine Biopharma (NASDAQ:SBFM
S&P Futures Muted With Focus on U.S. PCE Inflation Data and Nvidia Earnings
Zacks Investment Ideas feature highlights: Bloom Energy, Micron, Nvidia, UBS and Moderna
Don't Sleep On Software
Stocks Settle Higher as Lower Crude Prices Ease Inflation Risks
Wolfe Research Just Upgraded Moderna Stock. Here's Why.
Charts & Ideas
MRNA - Long-Term Technical Forecast
Weekly price is located above Ichimoku cloud in the bullish area of the chart for trying to cross the level at 81.36 to above for the strong bullish trend to be continuing. The price is on strong bullish breakout which is confirmed by Stochastic oscillator and Chinkou Span line. If the price breaks the 81.36 level to above on weekly close bar so the strong bullish trend will be continuing. If the price crosses the level at 73.28 to below so the secondary correction will be started. If the price breaks the support level at 43.90 to 36.66 to be crossed on weekly close bar so we may see the primary bearish reversal to be started on this W1 timeframe for example. Alternatively, the price will be on ranging to be near and above Ichimoku cloud waiting for direction. Trading Summary : bullish
The MRNA doesn’t have other trading ideas at this time
Browse ready-made trading ideas or select a symbol and create your own
Go to Charts and Trading Ideas